Overview

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z® plus AZOPT® in lowering intraocular pressure (IOP).

Phase:

Phase 2

Details

Lead Sponsor:

Alcon Research

Treatments:

Brinzolamide
Ophthalmic Solutions
Pharmaceutical Solutions
Travoprost